1-3 of 3
Inger S. Nijhof
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

Jakub Krejcik, Kris A. Frerichs, Inger S. Nijhof, Berris van Kessel, Jeroen F. van Velzen, Andries C. Bloem, Marloes E.C. Broekmans, Sonja Zweegman, Johan van Meerloo, René J.P. Musters, Pino J. Poddighe, Richard W.J. Groen, Christopher Chiu, Torben Plesner, Henk M. Lokhorst, A. Kate Sasser, Tuna Mutis, Niels W.C.J. van de Donk
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7498–7511.
https://doi.org/10.1158/1078-0432.CCR-17-2027
Published: 14 December 2017
View article titled, Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Open the PDF for Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab in another window
Includes: Supplementary data
Journal Articles

Abstract A12: Combination of the anti-CD38 monoclonal antibody daratumumab and all-trans retinoic acid.

Inger S. Nijhof, Henk M. Lokhorst, Berris van Kessel, Parul Doshi, Kate Sasser, Tuna Mutis, Niels WCJ van de Donk
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17_Supplement): A12.
https://doi.org/10.1158/1557-3265.HEMMAL14-A12
Published: 19 August 2015
View article titled, Abstract A12: Combination of the anti-CD38 monoclonal antibody daratumumab and all-trans retinoic acid.
Journal Articles

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

Inger S. Nijhof, Richard W.J. Groen, Willy A. Noort, Berris van Kessel, Regina de Jong-Korlaar, Joost Bakker, Jeroen J.L. van Bueren, Paul W.H.I. Parren, Henk M. Lokhorst, Niels W.C.J. van de Donk, Anton C.M. Martens, Tuna Mutis
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2802–2810.
https://doi.org/10.1158/1078-0432.CCR-14-1813
Published: 14 June 2015
View article titled, Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
Open the PDF for Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib in another window